Refine by
Pneumoniae Articles & Analysis: Older
105 news found
Global Handwashing Day is an international advocacy that emphasizes the importance of washing hands with water and soap as a simple yet effective way to prevent illnesses such as diarrhea and pneumonia. Celebrated every October, GHD is observed in over 1 million schools across 100 countries, engaging more than 200 million people worldwide. ...
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. ...
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. ...
“HAIs due to Klebsiella can include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis,” said Paul Cochrane, President of Cochrane & Associates and the IAQ Video Network. ...
Various types include: · Methicillin-resistant Staphylococcus aureus (MRSA) · Methicillin-susceptible Staphylococcus aureus (MSSA) · Vancomycin-intermediate Staphylococcus aureus (VISA) · Vancomycin-resistant Staphylococcus aureus (VRSA) “These infections may include bacteremia or sepsis, pneumonia, endocarditis ...
China is predicted to see two peaks in cases as COVID-19 spreads throughout the country, the first peak in mid-January and the second in early March. New modelling by Airfinity has examined data from China’s regional provinces. The current outbreak is growing more rapidly in some regions than in others. Cases are currently rising much more quickly in Beijing and Guangdong. Using the ...
Recent Highlights and Upcoming Milestones LungFit® PH Continue progress with limited release phase of commercial launch, making it the first and only nitric oxide generator, delivery and monitoring system available in the U.S., following FDA approval on June 28, 2022 to treat term and near-term neonates with hypoxic respiratory failure CE Mark anticipated to be received at the end of ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive data from the ...
Creative Diagnostics also offers a portfolio of vaccine R&D reagents, including over 40 native antigens of key infectious pathogens, such as Corynebacterium diphtheriae, Clostridium tetani, enterovirus, hepatitis virus, influenza virus, poliovirus, rotavirus, Streptococcus pneumoniae, and Zika virus. These antigens can be used for a variety of applications, from the ...
Crater, MD, FCCP, Chief Medical Officer, Inversago Pharma Thematic Poster Session 23 (TP-23): “Promising new approaches in idiopathic interstitial pneumonias” Date and Time: Monday, Sept. 5, 2022, 8:30-9:30am (CET) To register for ERS International Congress 2022, please visit ersnet.org. ...
If approved, landiolol, an ultra-short acting cardio-selective IV beta-blocker, and CAL02, a first-in-class anti-infective agent to treat severe bacterial pneumonia will join our currently approved products to create a formidable hospital/anesthesia product portfolio,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. ...
Ondine’s photodisinfection is a platform technology under development for a wide variety of conditions including presurgical decolonisation, and treatment of burns, wounds, ventilator-associated pneumonia, and chronic sinusitis. “The rising rates of COVID-19 due to rapidly evolving SARS-CoV-2 variants underline the importance of our broad-spectrum nasal ...
“We are pleased with the progress of our ongoing Phase 1/2 proof-of-concept study, which is now dosing participants in the Phase 2 portion designed to evaluate the safety, tolerability and immunogenicity of VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), for the prevention of invasive pneumococcal disease and pneumonia in adults,” said Grant Pickering, ...
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, ...
Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. ...
The trial demonstrates that using Unyvero HPN panel in hospitalized pneumonia patients for the examination of bronchoalveolar lavage (BAL) in combination with antibiotic stewardship decreases the duration of inappropriate antibiotic therapy of hospitalized patients with pneumonia at risk for Gram-negative bacteria and supports antibiotic de-escalation in 66% of ...
Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. ...
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, ...
This respiratory epithelium is essential to the avoidance of infections such as pneumonia. This pig lived almost two years until scheduled euthanasia. ...
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, ...